United Therapeutics Corporation reported its financial results for the first quarter of 2026, revealing total revenues of $781.5 million, a decrease of 1.6% from $794.4 million in the same period of 2025. The decline was primarily driven by a significant drop in sales of Nebulized Tyvaso, which fell by $36.6 million, offset by a $27.8 million increase in sales of Tyvaso DPI. The company’s net income for the quarter was $274.9 million, down from $322.2 million a year earlier, resulting in diluted earnings per share of $5.82 compared to $6.63 in the prior year.
Operating expenses increased to $455.7 million from $411.6 million, largely due to a rise in the cost of sales, which surged to $133.4 million from $92.5 million. This increase was attributed to higher inventory reserve expenses, including an estimated $26.8 million loss related to a commercial supply agreement for Tyvaso DPI. Research and development expenses also decreased to $138.2 million from $149.0 million, reflecting reduced milestone payments for drug delivery technologies.
In terms of strategic developments, United Therapeutics has been active in expanding its product offerings and market presence. The company is preparing to submit a supplemental New Drug Application (sNDA) for Nebulized Tyvaso to treat idiopathic pulmonary fibrosis (IPF) following successful Phase 3 trials. Additionally, the company is advancing its pipeline with plans to submit a New Drug Application for ralinepag extended-release tablets by the end of summer 2026. The company also completed the acquisition of Miromatrix Medical Inc., which focuses on developing manufactured organ alternatives.
Operationally, United Therapeutics reported a stable customer base, with total cash and cash equivalents decreasing to $1.28 billion from $1.56 billion at the end of 2025. The company’s marketable investments also saw a decline, totaling $2.59 billion compared to $3.14 billion previously. The company has initiated a $2 billion share repurchase program, with $1.5 billion already allocated to repurchasing shares under accelerated share repurchase agreements. Looking ahead, United Therapeutics anticipates revenue growth driven by the continued adoption of Tyvaso DPI, the launch of new products, and modest price increases, while navigating a competitive landscape that includes generic competition and new entrants in the pulmonary arterial hypertension market.
About UNITED THERAPEUTICS Corp
United Therapeutics is a biotech company focused on developing therapies for pulmonary arterial hypertension and other life-threatening diseases. It markets inhaled, injectable, and oral medications, and is pioneering organ manufacturing, xenotransplantation, and regenerative medicine to address organ shortages. Its core value lies in innovative treatments, advanced organ technologies, and sustainable delivery solutions, serving global markets with a focus on rare and severe conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.